BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Aldagen, Inc. 

2810 Meridian Parkway
Suite 148
Durham  North Carolina  27713  U.S.A.
Phone: 919-484-2571 Fax: 919-484-8792


SEARCH JOBS




Industry
Biotechnology






 Company News
Burrill & Company Advises Aldagen, Inc. (ALDH) in Sale of Its Next Generation Cell Therapy to Cytomedix Inc. (CMXI) 2/21/2012 9:03:47 AM
Cytomedix Inc. (CMXI) to Showcase Aldagen, Inc. (ALDH)'s Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings 2/16/2012 8:43:23 AM
Cytomedix Inc. (CMXI) Picks Up Aldagen, Inc. (ALDH) for $40 Million 2/9/2012 7:28:05 AM
Aldagen, Inc. (ALDH) Presents Data Describing Cell Therapy Products' Mechanism for Homing to Ischemic Injury 1/26/2012 9:00:12 AM
Aldagen, Inc. (ALDH) Announces Publication of Mechanism of Action Data for Its Cardiovascular Cell Therapy Products 11/16/2011 8:55:54 AM
Aldagen, Inc. (ALDH) Announces First Subject Enrolled and Clears Initial Safety Assessment in Phase 2 Stem Cell Study for Ischemic Stroke 6/2/2011 7:16:37 AM
Aldagen, Inc. (ALDH) Announces Publication of Phase 1/2 Results for ALD-301, a Stem Cell Therapy in Development for Critical Limb Ischemia 5/19/2011 9:06:23 AM
Aldagen, Inc. (ALDH) Pulls $80.5 Million IPO 4/6/2011 8:30:43 AM
Aldagen, Inc. (ALDH) Announces FDA Clearance of IND to Begin Phase 2 Study in Ischemic Stroke With Regenerative Cell Therapy 1/5/2011 10:02:38 AM
Aldagen, Inc. (ALDH) Announces Edward L. Field Appointed Vice Chairman of the Alliance for Regenerative Medicine 10/21/2010 9:22:51 AM
12345